Article

SMO mutation affects tumor immuno-microenvironment and predicts the effect of immune checkpoint inhibitor: from NSCLC to multiple-cancers

2022-05-27

Abstract excerpt

A critical and challenging process in immunotherapy is to identify cancer patients who could benefit from immune checkpoint inhibitors (ICIs). Exploration of predictive biomarkers could help to optimize the clinical benefits. SMO mutation was found to be enriched in patients responding to ICIs therapy. In the discovery NSCLC cohort ( N = 349 ), significant differences were detected between SMO_MUT and SMO_WT patie...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a0274ad3-3809-5ff3-95de-15d0370f6579
DOI: 10.21203/rs.3.rs-1691028/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

SMO mutation affects tumor immuno-microenvironment and predicts the effect of immune checkpoint inhibitor: from NSCLC to multiple-cancersDOI 10.21203/rs.3.rs-1691028/v1Read

SMO mutation predicts the effect of immune checkpoint inhibitor: From NSCLC to multiple cancers.Semantic proximity Read

Immunomodulatory role of oncogenic alterations in non-small cell lung cancer: a review of implications for immunotherapy.Semantic proximity Read

Association of EYS mutations with immune checkpoint inhibitor outcome and response in melanoma and non-small cell lung cancerSemantic proximity Read

Age, sex, and specific gene mutations affect the effects of immune checkpoint inhibitors in colorectal cancer.Semantic proximity Read

Tumor microenvironment changes after treatment with avelumab and immune- stimulating agent combinations in patients with advanced solid tumorsSemantic proximity Read

Influence of TP53 Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in STK11-Mutant Non–Small-Cell Lung CancerSemantic proximity Read

TP53/BRAF mutation as an aid in predicting response to immune-checkpoint inhibitor across multiple cancer types.Semantic proximity Read

Identification and validation of a genomic mutation signature as a predictor for immunotherapy in NSCLC.Semantic proximity Read

BRAF mutation predicts survival after immunotherapy across multiple cancer types.Semantic proximity Read

Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy.Semantic proximity Read

TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.Semantic proximity Read

Comprehensive analysis of multiple parameters associated with tumor immune microenvironment in ARID1A mutant cancers.Semantic proximity Read